Four Decades for Justice
Cravath represented the underwriters, led by J.P. Morgan Securities, SVB Leerink and BMO Capital Markets, in connection with the $115 million registered equity offering of Replimune Group, Inc., a biotechnology company developing oncolytic immuno‑gene therapies derived from its Immulytic™ platform. The offering consisted of shares of Replimune’s common stock and pre‑funded warrants to acquire shares of its common stock. The shares were listed on The Nasdaq Global Select Market. The transactions closed on June 11, 2020 and June 29, 2020.
The Cravath team included partner William V. Fogg and associates William F. Roegge, Eric S. Goodwin and Kevin L. Cheng on capital markets matters, partner Christopher K. Fargo and associates Richard M. Bohm and Carlos Nicholas Obando on tax matters, and practice area attorney Anthony N. Magistrale on intellectual property matters.
Deals & Cases
Cravath represented the underwriters, J.P. Morgan Securities, Leerink Partners and BMO Capital Markets, in connection with the $111 million initial public offering of the common stock of Replimune Group, Inc., a biotechnology company developing oncolytic immunotherapies derived from its Immulytic™ platform. The shares were listed on the Nasdaq Global Select Market. The transaction closed on July 24, 2018.
Celebrating 200 years of partnership. In 2019, we celebrated our bicentennial. Our history mirrors that of our nation. Integral to our story is our culture.
Attorney Advertising. ©2024 Cravath, Swaine & Moore LLP.